Radiotherapy of Stage I and II carcinomas of the mobile tongue and/or floor of the mouth

Bachaud, Jean-Marc; Delannes, M.; Allouache, N.; Benchalal, M.; Alzieu, Claude; David, Jean-Marc; Serrano, É.; Daly-Schveitzer, N.

doi:10.1016/0167-8140(94)90424-3

Cited by 34 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This signifies that brachytherapy alone is sufficient for T1 stage patients, and neck addressal is not required for these patients. The similar results have been described by various studies in literature too [1,3,4,6,10]. [23,24,25], by applying corrections for overall treatment time: T = 38 or 39 days = 28 days EBRT, 3 or 4 days brachytherapy boost (3 days when 18 Gy boost given in 3 days, and 4 days when 24 Gy boost given in 4 days), and 7 days gap prior to brachytherapy for mucosal reactions to heal), starting time of tumor repopulation (Tk = 21 days) and cell population doubling time during treatment done by EBRT and brachytherapy boost (Tp = 3 days):…”

Section: Discussionsupporting

confidence: 91%

“…The clinical outcome in terms of loco regional control rates and survival has been compared among the two groups in this study. The 5-year LCR of 64.2% seen in our patients, was quite lower than the rates reported in literature [2,6,12,13]. On subset analysis according to T stage, the 5 year LCR for stage I and stage II were 74.7% and 52.5%, respectively, which are again inferior compared to the previous reports [13,14,15,16].…”

Section: Discussioncontrasting

confidence: 88%

“…The late complications were seen in 32.9% of patients, however out of these, grade 3 complications in terms of induration, ankyloglossia, and bone necrosis were seen in 6 patients (6.5%) only. The complication rate is similar to the grade 3 complication rates of 3-15% mentioned in literature [4,5,6,10,34]. However, no correlation was found between the incidence of late complications and the BED of the two groups.…”

Section: Discussionsupporting

confidence: 84%

“…Interstitial implants also provide local control rates equivalent to that of surgery [1,3]. However, most of the results in literature have been described with continuous low-dose-rate brachytherapy (LDR-BT) [4,5,6,7,8,9,10]. With the evolution of afterloading techniques, high-dose-rate brachytherapy (HDR-BT) has replaced LDR-BT in most of the centers in the world.…”

Section: Purposementioning

confidence: 99%

See 3 more Smart Citations

High-dose-rate interstitial brachytherapy in early stage oral tongue cancer – 15 year experience from a tertiary care institute

Bansal¹,

Ghoshal²,

Oinam³

et al. 2016

jcb

View full text Add to dashboard Cite

Purpose: To determine outcomes of interstitial high-dose-rate brachytherapy (HDR-BT) in patients with early stage oral tongue cancer.Material and methods: Ninety-two patients with stage I and II oral tongue cancer were treated with HDR-BT between 1999 and 2014: brachytherapy alone = 62 (67.4%), and combination of external beam radiotherapy (EBRT) and brachytherapy = 30 (32.6%). Median follow-up was 53.5 months. Patterns of failure, overall survival (OS), disease-free survival (DFS), local control rates (LCR), and nodal control rates (NCR) were determined.Results: 5-year OS, DFS, LCR, and NCR were 73.2%, 58.2%, 64.2%, and 83.8%, respectively. In total, 43 patients (46.7%) failed treatment: isolated local failures = 28 (30.4%), isolated nodal failures = 8 (8.7%), both local and regional failures = 7 (7.6%). While in T1 stage, 5 year LCR were significantly higher in brachytherapy alone group compared to combined EBRT and brachytherapy group (81.7% vs. 62.5%, p = 0.04), the isolated nodal failure rates were not significantly different among the two groups. For T2 stage, NCR were higher in combined EBRT and brachytherapy group compared to brachytherapy alone (92.9% vs. 74.3%). Acute mucositis (grade ≥ 2) was seen more in brachytherapy alone group compared to the combined modality group (87% vs. 66%), and this correlated significantly with the higher biological equivalent dose (BED) in the brachytherapy alone group.Conclusions: Our study recommends treating patients with brachytherapy alone in T1 stage, and demonstrates the need for addressing nodal region either by neck dissection or nodal irradiation in T2 stage patients. Also, the study highlights the need for dose escalation (from the doses used in the study) in both T1 and T2 stage tumors when using interstitial brachytherapy either as sole modality or as a boost.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussioncontrasting

confidence: 88%

Section: Discussionsupporting

confidence: 84%

Section: Purposementioning

confidence: 99%

See 2 more Smart Citations

High-dose-rate interstitial brachytherapy in early stage oral tongue cancer – 15 year experience from a tertiary care institute

Bansal¹,

Ghoshal²,

Oinam³

et al. 2016

jcb

View full text Add to dashboard Cite

show abstract

“…Horiuchi et al (15) reported that patients with carcinoma of the mouth floor and the buccal mucosal accounted for 31.6% (56) and 23.7% therapy. These studies reported excellent results equivalent to those with a needle or hairpin source, especially for early tumors (T1 or T2) (7,11). With regard to cancer of the tongue, a negative indication for gold seed implantation has been determined (15).…”

Section: Discussionmentioning

confidence: 99%